NRCNRC Health
Is the price fair?
Neither cheap nor expensive: nothing decisive, though cheap against its own history.
Priced for ~6% a year FCF growth. Moderate growth expectations are priced in.
Cheap vs its own history: P/E 17.9 vs a 26.6 median over 24 quarters (−33% vs median).
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What NRC's price assumes
Today's price asks for 6.5% free cash flow growth a year; over the last three years NRC Health delivered 0.60%, the price is ahead of the record.
- Free cash flow yield
- 4.7%
Free cash flow yield · Health Information Services median 6.3%
- Growth the price implies
- +6.5%
Growth the price implies · The price pays for +6.5% free cash flow growth a year for a decade; the business has delivered +0.60% a year over the last three.
Details›
- Free cash flow, trailing twelve months
- $22M
- Market capitalisation
- $460M
- 3-year revenue growth
- −1.9%
- 3-year free cash flow growth
- +0.60%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $1,166.76 |
| Its own P/E history, median | $1,323.31 |
| Its own P/E history, upper quartile | $1,502.07 |
| 52-week range | $11.22 – $22.85 |
| Today | $20.41 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Health Information Services
Ranks #6 of 20 by RyuScore